|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006104,
umls-concept:C0007634,
umls-concept:C0021149,
umls-concept:C0030705,
umls-concept:C0228126,
umls-concept:C0679254,
umls-concept:C0684249,
umls-concept:C0871261,
umls-concept:C1122962,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2005-5-24
|
|
pubmed:abstractText |
Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor that induces an early and dramatic response in 10% of patients with advanced nonsmall cell lung carcinoma (NSCLC). Long- term outcome and patterns of disease recurrence after response have not been described.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
103
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2344-8
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15844174-Adult,
pubmed-meshheading:15844174-Aged,
pubmed-meshheading:15844174-Aged, 80 and over,
pubmed-meshheading:15844174-Antineoplastic Agents,
pubmed-meshheading:15844174-Brain Neoplasms,
pubmed-meshheading:15844174-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:15844174-Cohort Studies,
pubmed-meshheading:15844174-Female,
pubmed-meshheading:15844174-Humans,
pubmed-meshheading:15844174-Incidence,
pubmed-meshheading:15844174-Lung Neoplasms,
pubmed-meshheading:15844174-Male,
pubmed-meshheading:15844174-Meningeal Neoplasms,
pubmed-meshheading:15844174-Middle Aged,
pubmed-meshheading:15844174-Neoplasm Staging,
pubmed-meshheading:15844174-Quinazolines,
pubmed-meshheading:15844174-Receptor, Epidermal Growth Factor,
pubmed-meshheading:15844174-Survival Rate,
pubmed-meshheading:15844174-Treatment Failure
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
|
|
pubmed:affiliation |
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
|
|
pubmed:publicationType |
Journal Article
|
